Abstract

This study in dogs explored the feasibility of using cartilage fragments removed and discarded during routine palliative surgery for osteochondritis dissecans (OCD) as a source of primary chondrocytes for scaffold-free cartilage tissue-engineering. Primary chondrocytes were obtained from three OCD donors and one age-matched healthy articular cartilage (HAC) donor. After monolayer expansion of primary cells, a three-dimensional spherical suspension culture was implemented. Following this stage, cells were seeded at a high density into custom-made agarose molds that allowed for size and shape-specific constructs to be generated via a method of cellular self-assembling in a scaffold-free environment. Fifty-eight neocartilage constructs were tissue-engineered using this methodology. Neocartilage constructs and native cartilage from shoulder joint were subjected to histological, mechanical, and biochemical testing. OCD and HAC chondrocytes-sourced constructs had uniformly flat morphology and histology consistent with cartilage tissue. Constructs sourced from OCD chondrocytes were 1.5-times (32%) stiffer in compression and 1.3 times (23%) stronger in tension than constructs sourced from HAC chondrocytes and only 8.7-times (81%) less stiff in tension than native tissue. Constructs from both cell sources consistently had lower collagen content than native tissue (22.9%/dry weight [DW] for OCD and 4.1%/DW for HAC vs. 51.1%/DW native tissue). To improve the collagen content and mechanical properties of neocartilage, biological and mechanical stimuli, and thyroid hormone (tri-iodothyronine) were applied to the chondrocytes during the self-assembling stage in two separate studies. A 2.6-fold (62%) increase in compressive stiffness was detected with supplementation of biological stimuli alone and 5-fold (81%) increase with combined biological and mechanical stimuli at 20% strain. Application of thyroid hormone improved collagen content (1.7-times, 33%), tensile strength (1.8-times, 43%), and stiffness (1.3-times, 21%) of constructs, relative to untreated controls. Collectively, these data suggest that OCD chondrocytes can serve as a reliable cell source for cartilage tissue-engineering and that canine chondrocytes respond favorably to biological and mechanical stimuli that have been shown effective in chondrocytes from other animal species, including humans.

Highlights

  • The very low regenerative capacity of cartilage combined with a high demand for the joint return to function invite exploration of new strategies for replacement and regeneration of this tissue.37 The most common therapies currently available for the repair of cartilage are microfracture, autologous chondrocyte implantation with or without matrix (MACI and ACI, respectively), and autologous or allogeneic osteochondral grafts.17 MACI and ACI are the only FDAapproved cellular therapies available to patients to date in the US

  • This study is the first to demonstrate that chondrocytes derived from Osteochondritis Dissecans (OCD) cartilage fragments can be used to engineer scaffold-free neocartilage tissue

  • We found that chondrocytes isolated from OCD surgery fragments could form functional cartilage constructs with properties comparable to constructs engineered from healthy articular chondrocytes

Read more

Summary

Introduction

The very low regenerative capacity of cartilage combined with a high demand for the joint return to function invite exploration of new strategies for replacement and regeneration of this tissue. The most common therapies currently available for the repair of cartilage are microfracture, autologous chondrocyte implantation with or without matrix (MACI and ACI, respectively), and autologous or allogeneic osteochondral grafts. MACI and ACI are the only FDAapproved cellular therapies available to patients to date in the US. The very low regenerative capacity of cartilage combined with a high demand for the joint return to function invite exploration of new strategies for replacement and regeneration of this tissue.. The most common therapies currently available for the repair of cartilage are microfracture, autologous chondrocyte implantation with or without matrix (MACI and ACI, respectively), and autologous or allogeneic osteochondral grafts.. MACI and ACI are the only FDAapproved cellular therapies available to patients to date in the US. Microfracture results in the repair of a cartilage defect by fibrocartilage, which is less durable than hyaline articular cartilage.. Microfracture results in the repair of a cartilage defect by fibrocartilage, which is less durable than hyaline articular cartilage. Techniques that involve autologously sourced cells

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call